In the Chinese pharmaceutical industry, there were 25 M&A deals announced in Q3 2023, worth a total value of $602.1m, according to GlobalData’s Deals Database. The $159m majority acquisition of Diasys Diagnostic Systems (Shanghai) by Shenzhen Mindray Bio-Medical Electronics was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in China increased by 124% in Q3 2023 compared with the previous quarter’s total of $268.6m and fell by 60% as compared to Q3 2022. Related deal volume decreased by 4% in Q3 2023 versus the previous quarter and was 24% lower than in Q3 2022.
The top-ranked financial advisors supporting these M&A deals in China in Q3 2023 were China Dragon Securities; Hualong Securities; Lazard with 1, 1, 1 deals respectively.
The top-ranked legal advisorss supporting these M&A deals in China Q3 2023 were DeHeng Law Offices; Dorsey & Whitney; Freshfields Bruckhaus Deringer with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.